Navigation Links
Angiotech's Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
Date:8/11/2009

ts, events or developments expressed or implied by such forward-looking statements. Many such known risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions in the United States, Canada and the other regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; availability of financial reimbursement coverage from governmental and third-party payers for products and related treatments; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development, to expand manufacturing and commercialization activities; and any other factors that may affect our performance. In addition, our business is subject to certain operating risks that may cause any results expressed or implied by the forward-looking statements in this Quarterly Report on Form 10-Q to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in our business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third-party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference
2. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
3. Tutogen Medical, Inc. to Report Fourth Quarter and Fiscal Year 2007 Financial Results
4. Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results
5. Nonin Medical, Inc. Receives Frost & Sullivans 2007 Award for Product Differentiation Innovation
6. Tutogen Medical, Inc. Reports First Quarter Fiscal 2008 Financial Results
7. Arobella Medical, LLC Launches Qoustic Wound Therapy System(TM)
8. SBT Acquisition Inc. Successfully Completes Tender Offer for Shares of Lifecore Biomedical, Inc.
9. Tryton Medical, Inc. Closes $14 Million Financing
10. China Sky One Medical, Inc. Acquires Heilongjiang Haina Pharmaceutical Inc.
11. Cohera Medical, Inc. Announces Closing of Insider Round of Financing for Over $7.6 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... ... July 03, 2015 , ... ... products for use in applications such as animal waste reduction, bioremediation, wastewater ... and restaurant kitchen settings, announced today that it will be showcasing, ManureMagic™, ...
(Date:7/3/2015)... 3, 2015 ... osoitteessa  http://www.openinnovationinscience.at Wienissä pidettävään ... Science" -jatkokoulutusohjelmaan 22.7.2015 asti.  ... tekemän, kansainvälisiä tutkijoita ja tiedemiehiä ... suurinta haastetta ovat kannustimien puute ...
(Date:7/3/2015)... ... July 03, 2015 , ... The Alexander ... and professional service industries alike-- typically known for its consummate professionalism-- embarks each ... good cause and break from their day jobs. , "Our motto has always ...
(Date:7/3/2015)... ... ... The global failure analysis market is expected to reach $7,147.0 million by 2020, at ... grow at the highest CAGR of 8.46%; its growth is expected to be driven ... institutions for root cause analysis of failure. The market based on the geographic regions ...
Breaking Biology Technology:DryLet to Highlight Benefits of Patented ManureMagic™ at North American Manure Expo in Chambersburg, PA July 14-15, 2015 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3The Alexander Group Declares Their Independence with a Bit of Levity 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 4Failure Analysis Market to Grow at 7.52% CAGR to 2020 5
... BEACH, Va., May 8 LifeNet Health, a,leading ... was awarded an Excellence in Innovation award at ... in Hampton, Virginia., The Excellence in Innovation ... most innovative patents that were filed from within,the ...
... Attack Deaths by Shielding ... High-Risk Plaques in Coronary Arteries, DOYLESTOWN, ... medical device company dedicated to reducing deaths from,heart attacks, ... treatment of rupture-prone or "vulnerable" plaques,with a focus on ...
... May 8 BioCryst,Pharmaceuticals, Inc. (Nasdaq: BCRX ) today ... Company reported revenues of $10.8M,in the first quarter of 2008, ... loss for the quarter ended March 31, 2008 was $13.1M, ... quarter ended March 31,2007 of $8.8M, or $0.30 per share., ...
Cached Biology Technology:LifeNet Health Chief Scientific Officer Wins Award 2Prescient Medical, Inc. to Present Data on Identification and Treatment of Rupture-Prone Coronary Plaques at EuroPCR 2008 2BioCryst Reports First Quarter 2008 Financial Results and Clinical Update 2BioCryst Reports First Quarter 2008 Financial Results and Clinical Update 3BioCryst Reports First Quarter 2008 Financial Results and Clinical Update 4BioCryst Reports First Quarter 2008 Financial Results and Clinical Update 5BioCryst Reports First Quarter 2008 Financial Results and Clinical Update 6BioCryst Reports First Quarter 2008 Financial Results and Clinical Update 7BioCryst Reports First Quarter 2008 Financial Results and Clinical Update 8
(Date:6/24/2015)... 2015 This report provides market analysis of ... years. It contains an analysis of the drivers, challenges, ... impact from the short, medium, and long term perspective ... market, and technology trends that currently, prevail in the ... authorities to efficiently manage the increasing marine traffic and ...
(Date:6/24/2015)... , June 24, 2015 Biometry ... with emerging biometric password solution one face in. ... one face in, entering the ... ground-breaking and affordable multifactor-authentication biometric answer to the ... technology, provided in partnership with KeyLemon, one face ...
(Date:6/23/2015)... June 23, 2015   Valencell, a ... results of a recent study that illustrates its ... wrist during activity. In a study conducted at ... along with the Apple Watch against a chest ... rate during activity. The study demonstrated that Valencell,s ...
Breaking Biology News(10 mins):Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... Researchers at the David Geffen School of Medicine at ... proteins known as sodium glucose co-transporters (SGLTs), which pump ... the treatment of chronic diarrhea via oral rehydration therapy, ... The solution of the SGLT structure will accelerate development ...
... have provided vital information to relief workers in Myanmar ... devastating Cyclone Nargis that hit the country on 2 ... the UN Office for the Coordination of Humanitarian Affairs ... Disasters, referred to as ,the Charter, for support by ...
... Want to slow the signs of aging and live longer? ... could be a promising strategy. Calorie restriction has ... and mice. While scientists do not know how calorie restriction ... that it slows aging by decreasing a thyroid hormone, triiodothyronine ...
Cached Biology News:UCLA researchers clarify function of glucose transport molecule 2Extended cyclone relief efforts aided from space 2Extended cyclone relief efforts aided from space 3Looking for the Founatain of Youth? Cut your calories, research suggests 2
RABBIT ANTI HALOPERIDOL...
Form: Ready to use Applications: Western Blot, ELISA...
... Bench-Top Open System Chemistry Analyzer for General Chemistries, Specialty Chemistries, QC, Reagent Development, Pharmaceutical ... grating, diode spectrophotometer over 30 user-selectable wavelengths. ... ... ...
2,4,6, Trinitrophenyl hapten is conjugated to lipopolysaccharide (LPS)....
Biology Products: